An exploration of mercaptopurine/methotrexate tolerance during maintenance therapy in children with acute lymphoblastic leukemia.

A C WhileyV PriceTamara MacDonald

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Few patients complete maintenance therapy without interruptions at the current dose escalation schedules outlined by the Children's Oncology Group protocols. The interruptions are due in part to intolerance of dose escalations of MTX and 6 MP above 100%. Future research should investigate doses of 6MP and MTX in maintenance therapy in relation to leukemia outcomes.

Keyphrases

acute lymphoblastic leukemia
end stage renal disease
young adults
ejection fraction
chronic kidney disease
type diabetes
acute myeloid leukemia
randomized controlled trial
clinical trial
stem cells
high dose
metabolic syndrome
study protocol
glycemic control